MEDICALLY REVIEWED

A New Paradigm in Severe Burn Treatment – FDA Approves Anacaulase (NexoBrid®)

Burn Treatment
In Dec 2022, the US Food and Drug Administration (FDA) approved MediWound’s biologic license application (BLA) for anacaulase-bcdb (NexoBrid®)

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: